Section Arrow
PLRX.NASDAQ
- Pliant Therapeutics
Quotes are at least 15-min delayed:2024/06/01 01:32 EDT
Last
 12.12
-0.05 (-0.41%)
Day High 
12.61 
Prev. Close
12.17 
1-M High
16.52 
Volume 
447.62K 
Bid
10
Ask
12.88
Day Low
12.01 
Open
12.29 
1-M Low
11.73 
Market Cap 
734.17M 
Currency USD 
P/E -- 
%Yield
10-SMA 13.86 
20-SMA 13.88 
50-SMA 13.75 
52-W High 24.74 
52-W Low 11.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.86/-3.48
Enterprise Value
744.22M
Balance Sheet
Book Value Per Share
7.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.58M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.5285-0.0308-5.51%-- 
SMMTSummit Therapeutics8.685-2.235-20.47%28.74PE
KTRAKintara Therapeutics0.3166-0.0004-0.13%-- 
SRPTSarepta Therapeutics129.86+5.41+4.35%289.42PE
NVAXNovavax15.03-0.22-1.44%-- 
Quotes are at least 15-min delayed:2024/06/01 01:32 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.